Research Paper
Effectiveness and outcome predictors of long-term lithium prophylaxis in unipolar major depressive disorder
Christopher Baethge, Philipp Gruschka, Michael N. Smolka, Anne Berghöfer, Tom Bschor, Bruno Müller-Oerlinghausen and Michael Bauer
J Psychiatry Neurosci September 01, 2003 28 (5) 355-361;
Christopher Baethge
Baethge — Consolidated Department of Psychiatry, Harvard Medical School, the Bipolar and Psychotic Disorders Program, McLean Division of Massachusetts General Hospital, Belmont, Mass., and the Department of Psychiatry and Psychotherapy, Universitätsklinikum Benjamin Franklin, Freie Universität Berlin; Gruschka — Department of Psychiatry, Ruprecht-Karls-Universität, Heidelberg; Smolka — Department of Addictive Behaviour and Addiction Medicine, Central Institute of Mental Health, Mannheim; Berghöfer — Institute of Social Medicine, Epidemiology and Health Economics, Charité, Humboldt-University of Berlin; Bschor — Department of Psychiatry and Psychotherapy, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden; Müller-Oerlinghausen — Drug Commission of the German Medical Association, Berlin/Cologne; Bauer — Department of Psychiatry and Psychotherapy, Charité, Humboldt-University of Berlin, Germany
MDPhilipp Gruschka
Baethge — Consolidated Department of Psychiatry, Harvard Medical School, the Bipolar and Psychotic Disorders Program, McLean Division of Massachusetts General Hospital, Belmont, Mass., and the Department of Psychiatry and Psychotherapy, Universitätsklinikum Benjamin Franklin, Freie Universität Berlin; Gruschka — Department of Psychiatry, Ruprecht-Karls-Universität, Heidelberg; Smolka — Department of Addictive Behaviour and Addiction Medicine, Central Institute of Mental Health, Mannheim; Berghöfer — Institute of Social Medicine, Epidemiology and Health Economics, Charité, Humboldt-University of Berlin; Bschor — Department of Psychiatry and Psychotherapy, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden; Müller-Oerlinghausen — Drug Commission of the German Medical Association, Berlin/Cologne; Bauer — Department of Psychiatry and Psychotherapy, Charité, Humboldt-University of Berlin, Germany
MDMichael N. Smolka
Baethge — Consolidated Department of Psychiatry, Harvard Medical School, the Bipolar and Psychotic Disorders Program, McLean Division of Massachusetts General Hospital, Belmont, Mass., and the Department of Psychiatry and Psychotherapy, Universitätsklinikum Benjamin Franklin, Freie Universität Berlin; Gruschka — Department of Psychiatry, Ruprecht-Karls-Universität, Heidelberg; Smolka — Department of Addictive Behaviour and Addiction Medicine, Central Institute of Mental Health, Mannheim; Berghöfer — Institute of Social Medicine, Epidemiology and Health Economics, Charité, Humboldt-University of Berlin; Bschor — Department of Psychiatry and Psychotherapy, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden; Müller-Oerlinghausen — Drug Commission of the German Medical Association, Berlin/Cologne; Bauer — Department of Psychiatry and Psychotherapy, Charité, Humboldt-University of Berlin, Germany
MDAnne Berghöfer
Baethge — Consolidated Department of Psychiatry, Harvard Medical School, the Bipolar and Psychotic Disorders Program, McLean Division of Massachusetts General Hospital, Belmont, Mass., and the Department of Psychiatry and Psychotherapy, Universitätsklinikum Benjamin Franklin, Freie Universität Berlin; Gruschka — Department of Psychiatry, Ruprecht-Karls-Universität, Heidelberg; Smolka — Department of Addictive Behaviour and Addiction Medicine, Central Institute of Mental Health, Mannheim; Berghöfer — Institute of Social Medicine, Epidemiology and Health Economics, Charité, Humboldt-University of Berlin; Bschor — Department of Psychiatry and Psychotherapy, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden; Müller-Oerlinghausen — Drug Commission of the German Medical Association, Berlin/Cologne; Bauer — Department of Psychiatry and Psychotherapy, Charité, Humboldt-University of Berlin, Germany
MDTom Bschor
Baethge — Consolidated Department of Psychiatry, Harvard Medical School, the Bipolar and Psychotic Disorders Program, McLean Division of Massachusetts General Hospital, Belmont, Mass., and the Department of Psychiatry and Psychotherapy, Universitätsklinikum Benjamin Franklin, Freie Universität Berlin; Gruschka — Department of Psychiatry, Ruprecht-Karls-Universität, Heidelberg; Smolka — Department of Addictive Behaviour and Addiction Medicine, Central Institute of Mental Health, Mannheim; Berghöfer — Institute of Social Medicine, Epidemiology and Health Economics, Charité, Humboldt-University of Berlin; Bschor — Department of Psychiatry and Psychotherapy, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden; Müller-Oerlinghausen — Drug Commission of the German Medical Association, Berlin/Cologne; Bauer — Department of Psychiatry and Psychotherapy, Charité, Humboldt-University of Berlin, Germany
MDBruno Müller-Oerlinghausen
Baethge — Consolidated Department of Psychiatry, Harvard Medical School, the Bipolar and Psychotic Disorders Program, McLean Division of Massachusetts General Hospital, Belmont, Mass., and the Department of Psychiatry and Psychotherapy, Universitätsklinikum Benjamin Franklin, Freie Universität Berlin; Gruschka — Department of Psychiatry, Ruprecht-Karls-Universität, Heidelberg; Smolka — Department of Addictive Behaviour and Addiction Medicine, Central Institute of Mental Health, Mannheim; Berghöfer — Institute of Social Medicine, Epidemiology and Health Economics, Charité, Humboldt-University of Berlin; Bschor — Department of Psychiatry and Psychotherapy, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden; Müller-Oerlinghausen — Drug Commission of the German Medical Association, Berlin/Cologne; Bauer — Department of Psychiatry and Psychotherapy, Charité, Humboldt-University of Berlin, Germany
MDMichael Bauer
Baethge — Consolidated Department of Psychiatry, Harvard Medical School, the Bipolar and Psychotic Disorders Program, McLean Division of Massachusetts General Hospital, Belmont, Mass., and the Department of Psychiatry and Psychotherapy, Universitätsklinikum Benjamin Franklin, Freie Universität Berlin; Gruschka — Department of Psychiatry, Ruprecht-Karls-Universität, Heidelberg; Smolka — Department of Addictive Behaviour and Addiction Medicine, Central Institute of Mental Health, Mannheim; Berghöfer — Institute of Social Medicine, Epidemiology and Health Economics, Charité, Humboldt-University of Berlin; Bschor — Department of Psychiatry and Psychotherapy, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden; Müller-Oerlinghausen — Drug Commission of the German Medical Association, Berlin/Cologne; Bauer — Department of Psychiatry and Psychotherapy, Charité, Humboldt-University of Berlin, Germany
PhD, MD
Submit a Response to This Article
Jump to comment:
No Responses have been published for this article.
In this issue
J Psychiatry Neurosci
Vol. 28, Issue 5
1 Sep 2003
Article tools
Effectiveness and outcome predictors of long-term lithium prophylaxis in unipolar major depressive disorder
Christopher Baethge, Philipp Gruschka, Michael N. Smolka, Anne Berghöfer, Tom Bschor, Bruno Müller-Oerlinghausen, Michael Bauer
J Psychiatry Neurosci Sep 2003, 28 (5) 355-361;
Related Articles
- No related articles found.
Cited By...
- No citing articles found.